Discover the Divis Labs Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

Stay up-to-date with the Divis Labs Stock Liveblog, your trusted source for real-time updates and thorough analysis of a ...

Vinay Rajani of HDFC Securities says Divis Labs share price has broken out from the box pattern on the daily chart with the ...

The shares of this pharma stock, engaged in the manufacturing and exporting of API's and Nutraceutical ingredients, are in focus after leading global brokerage, CITI, has expressed its bullishness ...

Citi said it believes Divi's Laboratories' revenue and earnings before interest, tax, depreciation, and amortisation (EBITDA) ...

Earnings call Divi's Laboratories reported a 17% YoY revenue growth in Q2 FY26, driven by a record 56% contribution from custom synthesis. Margins remained resilient despite ongoing generic pricing ...

Multiple experts are converging on select pharma, FMCG, media, and financial services counters. Key names on today’s radar ...

Divi’s Laboratories’ (Divi’s) Q2FY26 result was in line with our expectations on all fronts. Constant currency growth slowed down to ~10.8% vs. 15% QoQ and 18% in FY25. Q2 growth was largely led by ...

Amid the rising volatility in the Indian equity markets, domestic brokerage firm BP Equities has shared its top picks for ...

Divi’s Laboratories (DIVI) Q2FY26 EBITDA was a beat; 7% above our estimates led by higher CS revenues. We expect margins to improve, led by better product mix and stable raw material prices. Mgmt.

Divis Laboratories Ltd has informed BSE that it has had a successful inspection by the US-FDA from 16th to 20th June, 2014, without any observations, for its Unit-I at vill. Lingojigudem, Choutuppal ...

HYDERABAD, Feb 3 (Reuters) - India's Divi's Laboratories (DIVI.NS), opens new tab reported a better-than-expected quarterly profit on Monday, aided by strong performance of its business that focuses ...